Novosom
Halle
About Novosom
Novosom is working with its partners to develop unique antisense, DNAi and siRNA based therapeutics with a current focus in inflammation, oncology and liver diseases. Novosom’s Smarticles® liposomal vectors allow partners to deliver their active substance (siRNA, antisense, decoy etc) inside the cell either for topical or systemic applications. Smarticles are an enabler of systemic treatments and an enhancer of topical treatments. The Company has several active therapeutically-relevant collaborations in oncology and inflammation. Novosom AG main investors include IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH and MBG Mittelständische Beteiligungs-gesellschaft Sachsen Anhalt.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Website: novosom.com
- Phone: +49 345 55 59 836
Social Profiles
Canonical: https://fsome.com/organization/novosom-2279329 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.